Syros Pharmaceuticals, Inc.SYRS
| Dec 31,
2016 | Dec 31,
2017 | Dec 31,
2018 | Dec 31,
2019 | Dec 31,
2020 | Dec 31,
2021 | Dec 31,
2022 |
|---|
| Net loss | - | - | -62 | -75 | -84 | -87 | -95 |
|---|
| Depreciation and amortization | 1 | 2 | 2 | 3 | 3 | 3 | 3 |
|---|
| Amortization of right-of-use asset | - | - | - | 0 | 0 | 0 | 0 |
|---|
| Transaction costs allocated to warrants issued in connection with private placement | - | - | - | - | - | - | 5 |
|---|
| Loss on disposal of fixed assets | -0 | - | - | - | - | - | - |
|---|
| Stock-based compensation expense | 4 | 4 | 7 | 10 | 11 | 10 | 11 |
|---|
| Fair Value Adjustment of Warrants | - | - | - | - | 0 | -17 | -43 |
|---|
| Net amortization of premiums and discounts on marketable securities | -0 | 0 | 1 | 1 | 0 | -0 | -0 |
|---|
| Amortization of debt-discount and accretion of deferred debt costs | - | - | - | - | 0 | 1 | 1 |
|---|
| Prepaid expenses and other current assets | 1 | -0 | 1 | 1 | -0 | 1 | 3 |
|---|
| Accounts receivable | 0 | -1 | - | 20 | -20 | -0 | - |
|---|
| Contract assets | - | - | - | - | 2 | 1 | -1 |
|---|
| Other long-term assets | 0 | 0 | 0 | - | 1 | 1 | 2 |
|---|
| Accounts payable | -0 | 0 | 1 | 1 | -1 | 0 | 3 |
|---|
| Accrued expenses | 4 | 4 | 4 | -4 | 1 | 5 | 2 |
|---|
| Deferred revenue | - | - | 10 | 18 | -6 | -12 | -6 |
|---|
| Proceeds for tenant improvement incentive from landlord | - | - | - | 7 | 2 | - | - |
|---|
| Operating lease asset and liabilities | - | - | - | -1 | 0 | 1 | 1 |
|---|
| Net cash used in operating activities | - | -45 | -40 | -60 | -57 | -100 | -123 |
|---|
| Purchases of property and equipment | 2 | 1 | 1 | 13 | 3 | 1 | 1 |
|---|
| Proceeds from Sale of Property, Plant, and Equipment | - | - | 0 | 0 | - | - | - |
|---|
| Purchases of marketable securities | 25 | 42 | 97 | 108 | - | 51 | - |
|---|
| Maturities of marketable securities | - | 27 | 88 | 109 | 50 | - | 68 |
|---|
| Net cash (used in) provided by investing activities | - | -16 | -11 | -12 | 47 | -53 | 67 |
|---|
| Payments on financing lease obligations | - | - | - | - | - | 0 | 0 |
|---|
| Proceeds from Stock Plans | - | - | - | 0 | 0 | 0 | 0 |
|---|
| Proceeds from Stock Options Exercised | - | - | - | - | - | - | 0 |
|---|
| Payment to creditor related to debt modification | - | - | - | - | - | - | 0 |
|---|
| Gross proceeds from common stock | 0 | 32 | 69 | 1 | 12 | - | - |
|---|
| Proceeds from Debt, Net of Issuance Costs | - | - | - | - | 40 | - | - |
|---|
| Cash and cash equivalents acquired in connection with merger,net of issuance costs paid | - | - | - | - | - | - | 12 |
|---|
| Proceeds from issuance of common stock and accompanying warrants and pre-funded warrants in private placement, net of issuance costs | - | - | - | - | 90 | - | 120 |
|---|
| Proceeds From Issuance Of Common Stock And Warrants In Public Offering Net Of Issuance Costs | - | - | - | - | - | 70 | - |
|---|
| Cash paid in lieu of fractional shares due to the reverse stock split | - | - | - | - | - | - | 0 |
|---|
| Proceeds From Issuance Of Convertible Preferred Stock And Accompanying Warrants In Public Offering Net Of Issuance Costs | - | - | - | 5 | - | - | - |
|---|
| Payment of issuance costs related to out of period offering | - | - | - | - | - | 0 | 0 |
|---|
| Net cash provided by financing activities | - | 34 | 69 | 66 | 143 | 71 | 131 |
|---|
| Net increase (decrease) in cash, cash equivalents and restricted cash | - | - | 18 | -6 | 132 | -82 | 75 |
|---|
| Cash paid for interest | - | 0 | 0 | 0 | 2 | 3 | 3 |
|---|
| Cash paid for tax | - | - | - | 0 | 0 | - | - |
|---|
| Capital Expenditures Incurred but Not yet Paid | 0 | 0 | 0 | 2 | 0 | 0 | - |
|---|
| Asset acquired under operating lease | - | - | - | 16 | - | - | - |
|---|
| Assets acquired under financing lease | - | - | - | 1 | - | - | - |
|---|
| Deferred debt financing costs incurred but unpaid as of period end | - | - | - | 0 | 0 | 0 | - |
|---|
| Offering Cost Incurred But Not Yet Paid | - | 0 | - | 0 | 0 | 0 | 0 |
|---|